AstraZeneca/Targacept's ispronicline fails in schizophrenia
This article was originally published in Scrip
Executive Summary
AstraZenecaand Targacept's neuronal nicotinic receptor agonist, ispronicline (AZD-3480), has failed to meet its primary endpoints in the Phase IIb HALO trial in cognitive dysfunction in schizophrenia.